Bristol-Myers Squibb Compnay

Janssen Biotech, Inc.

Five Prime Therapeutics, Inc.

Michael Quigley

Paul O Sheppard

Mark J Selby

Alan J Korman

Mohan Srinivasan

Nils Lonberg

Kent B Thudium

Han Chang

Mark F Maurer

Xi-Tao Wang

Thomas D Kempe

Arvind Rajpal

Guodong Chen

Maria N Jure-Kunkel

Ginger Chao Rakestraw

Aaron Paul Yamniuk

Richard Y Huang

Alexey Teplyakov

Changyu Wang

Karla Ann Henning

Indrani Chakraborty

Michelle Minhua Han

Brenda L Stevens

Hadia Lemar

Jochem Gokemeijer

Alexander T Kozhich

Susan Chien-Szu Wong

Xiang Shao

Zhehong Cai

Christina Maria Milburn

Andressa Smith

Johan Fransson

Keith Sadoon Bahjat

Bryan C Barnhart

Marie-Michelle Navarro Garcia

Patrick Guirnalda

Ekaterina G Deyanova

Akbar Nayeem

Hong Mimi Zhou

Ming Lei

Robert J Johnston

Andrew Rankin

John J Engelhardt

Lin Hui Su

Sandra V Hatcher

Luis Borges

Liang Schweizer

Xiaodi Deng

Paul H Kim

Jason Robert Pinckney

David A Critton

Chan Gao

Praveen Aanur

Marie-Claude Gaudreau

Zheng Yang

Christine Huang

Yan Feng

Maria Rodriguez

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Antibodies binding to vista at acidic pH

Provided herein are methods of treating cancer using agonistic antibodies that specifically bind to immunostimulatory receptors, wherein the antibodies are administered in an amount and/or frequency sufficient to achieve and/or maintain a receptor occupancy of less than about 80%, for example, a receptor occupancy of about 20% to about 80%. Also provided are methods of determining human doses for such agonistic antibodies, and methods for monitoring receptor occupancy of the agonistic antibodies in order to maintain effective antibody levels in, e.g., human patients. Also provided are methods of measuring soluble OX40 in a subject. Also provided are methods of treating cancer, comprising administering to the subject an effective amount of each of an anti-OX40 antibody and an anti-PD-1 antibody.

Immunostimulatory agonistic antibodies for use in treating cancer

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against OX-40 and uses thereof

The present invention is directed to methods for treating cancer, preferably a solid tumor or hematological malignancy, including for example pancreatic cancer, lung cancer (including but not limited to non-small cell lung cancer (NSCLC)), prostate cancer, colorectal cancer, breast cancer, melanoma or non-Hodgkin's lymphoma, comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) a small molecule CSF-1R inhibitor and (b) an agonistic antibody that binds CD40.

Co-therapy comprising a small molecule CSF-1R inhibitor and an agonistic antibody that specifically binds CD40 for the treatment of cancer

Antibodies against OX40 and uses thereof

The present invention relates to agonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies or antigen-binding fragments, and methods of making and using the foregoing.

Agonistic antibodies specifically binding CD40 and methods of use

Growing community of inventors

Ambler, PA, United States of America

Michael Quigley